在肺高血压大鼠中,西尔德纳菲尔对心房内尿酸水平的影响
Mukhallad A Aljanabi1, Nasr Alrabadi2, Sahar H Mahmoud1
1Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.
概括
在患有肺高血压 (PH) 的老鼠中,预防性西尔代纳菲尔治疗显著降低了心房内尿酸 (ANP) 水平和心脏缩. 这表明西尔代纳菲尔.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 动物模型 动物模型
背景情况:
- 肺高血压 (PH) 导致血管变化,右心室缩和心力衰竭.
- 作为血管扩张剂的西尔德纳菲尔显示出调节PH的潜力.
研究的目的:
- 为了评估西尔代纳菲尔在减轻单氨酸 (MCT) 诱导的PH在老鼠中的疗效.
- 在PH模型中评估西尔代纳菲尔对心房 natriuretic (ANP) 水平的影响.
主要方法:
- 成年雄性大鼠被随机分配到控制,MCT诱导的PH,MCT+西尔德纳菲尔逆转和MCT+西尔德纳菲尔预防组.
- 在逆转和预防手臂中,三周内每天服用50mg/kg的西尔德纳菲尔.
- 评估的关键参数包括ANP水平,富尔顿指数和氧化水平.
主要成果:
- 与MCT治疗和逆转组相比,预防性西尔代纳菲尔显著降低了ANP水平.
- 预防组与逆转组相比,富尔顿指数比率在预防组显著降低.
- 与对照组相比,逆转组的氧化水平较高.
结论:
- 预防性西尔代纳菲尔的使用有效地降低了ANP水平.
- 西尔德纳菲尔在PH的老鼠模型中显示出对MCT诱导的心脏缩的保护作用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Antihypertensive Drugs: Vasodilators
505
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
505
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
618
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
618
Antihypertensive Drugs: Angiotensin II Receptor Blockers
714
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
714


